Chu 2006c.
Methods | 4‐Week dietary stabilisation period 3‐Month before‐and‐after study |
|
Participants | 32 men and women with hypercholesterolaemia; TC > 200 mg/dL (5.17 mmol/L), LDL‐C > 130 mg/dL (3.36 mmol/L) Exclusion criteria: any acute illness, leukocytosis, thrombocytosis, chronic inflammatory disease, connective tissue disease, individuals with ACS within 6 months of enrolment Baseline TC: 6.60 mmol/L (255 mg/dL) Baseline LDL‐C: 4.61 mmol/L (178 mg/dL) Baseline HDL‐C: 1.09 mmol/L (42 mg/dL) Baseline TG: 1.76 mmol/L (156 mg/dL) |
|
Interventions | Atorvastatin 10 mg/d | |
Outcomes | Per cent change from baseline at 3 months of serum TC, LDL‐C, HDL‐C and TG | |
Notes | SDs were imputed | |
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | Atorvastatin 10 mg/d; intervention was analysed, and as no placebo group was included for comparison, assessment of random sequence generation is not applicable |
Allocation concealment (selection bias) | Unclear risk | Atorvastatin 10 mg/d; intervention was analysed, and as no placebo group was included for comparison, assessment of allocation concealment is not applicable |
Blinding (performance bias and detection bias) All outcomes | Unclear risk | Atorvastatin 10 mg/d; intervention was analysed, and as no placebo group was included for comparison, blinding status is not applicable |
Incomplete outcome data (attrition bias) All outcomes | Low risk | Data on all participants were reported |
Selective reporting (reporting bias) | Low risk | All lipid parameters were measured |
Other bias | Low risk | The study appears to be free of other sources of bias |